According to a research report published this morning, Imperial Capital has downgraded Rotech Healthcare ROHI from Outperform to In-Line, and lowered PT from $2 to $1.
In the report, Imperial Capital said, "At current levels, we believe Rotech shares are effectively trading with option value should the company manage its future Medicare cuts and/or be acquired/merge with a national competitor. Our view is supported by management's historical ability to respond to operational and reimbursement challenges."
Rotech Healthcare is currently trading at $0.64.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in